<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">Endothelial dysfunction</z:e> may precede development of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>We tested the hypothesis that elevated levels of hemostatic markers of <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e>, plasminogen activator inhibitor-1 (PAI-1) antigen, and <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor (vWF) antigen predicted incident <z:mp ids='MP_0002055'>diabetes</z:mp> independent of other <z:mp ids='MP_0002055'>diabetes</z:mp> risk factors </plain></SENT>
<SENT sid="2" pm="."><plain>We followed 2,924 Framingham Offspring subjects (54% women, mean age 54 years) without <z:mp ids='MP_0002055'>diabetes</z:mp> at baseline (defined by treatment, fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> &gt; or =7 or 2-h postchallenge <z:chebi fb="105" ids="17234">glucose</z:chebi> &gt; or =11.1 mmol/l) over 7 years for new cases of <z:mp ids='MP_0002055'>diabetes</z:mp> (treatment or fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> &gt; or =7.0 mmol/l) </plain></SENT>
<SENT sid="3" pm="."><plain>We used a series of regression models to estimate relative risks for <z:mp ids='MP_0002055'>diabetes</z:mp> per interquartile range (IQR) increase in PAI-1 (IQR 16.8 ng/ml) and vWF (IQR 66.8% of control) conditioned on baseline characteristics </plain></SENT>
<SENT sid="4" pm="."><plain>Over follow-up, there were 153 new cases of <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Age- and sex-adjusted relative risks of <z:mp ids='MP_0002055'>diabetes</z:mp> were 1.55 per IQR for PAI-1 (95% CI 1.41-1.70) and 1.49 for vWF (1.21-1.85) </plain></SENT>
<SENT sid="6" pm="."><plain>These effects remained after further adjustment for <z:mp ids='MP_0002055'>diabetes</z:mp> risk factors (including physical activity; <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi>, <z:chebi fb="0" ids="17855">triglyceride</z:chebi>, and blood pressure levels; smoking; parental history of <z:mp ids='MP_0002055'>diabetes</z:mp>; use of alcohol, <z:chebi fb="2" ids="35475">nonsteroidal anti-inflammatory drugs</z:chebi>, exogenous <z:chebi fb="0" ids="50114">estrogen</z:chebi>, or <z:hpo ids='HP_0000822'>hypertension</z:hpo> therapy; and <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo>), waist circumference, homeostasis model assessment of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, and <z:mp ids='MP_0001845'>inflammation</z:mp> (assessed by levels of C-reactive protein): the adjusted relative risks were 1.18 per IQR for PAI-1 (1.01-1.37) and 1.39 for vWF (1.09-1.77) </plain></SENT>
<SENT sid="7" pm="."><plain>We conclude that in this community-based sample, plasma markers of <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> increased risk of incident <z:mp ids='MP_0002055'>diabetes</z:mp> independent of other <z:mp ids='MP_0002055'>diabetes</z:mp> risk factors including <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, and <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
</text></document>